Neoprobe Corporation (NEOP), a diversified developer of innovative oncology surgical and diagnostic products, announced that results from a Phase II study of Lymphoseek® (Tilmanocept) have been published online in the Annals of Surgical Oncology and demonstrate the tracing agent's ability to identify tumor-draining lymph nodes in breast cancer and melanoma patients...
More...